From: Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients?
PJ | Placebo | P*****for PJ vs. placebo at zero time and at 12 m | ||||||
---|---|---|---|---|---|---|---|---|
Time | N | Mean ± SE (mm Hg) | P for trend | N | Mean ± SE (mm Hg) | P for trend | ||
SBP† | 0 | 44 | 145.6 ± 21.9 | 0.001 | 21 | 129.6 ± 27.2 | 0.15 | 0.28 |
3 M | 143.6 ± 23.9 | 131.2 ± 25.5 | ||||||
6 M | 141.7 ± 20.4 | 138.8 ± 24.8 | ||||||
12 M | 135.7 ± 21.3* | 135.6 ± 27.7 | 0.96 | |||||
SBP ≥ 140 at study initiation | 0 | 26 | 157.8 ± 12.9 | <0.001 | 5 | 162.0 ± 10.6 | 0.42 | 0.54 |
3 M | 153.2 ± 18.8 | 157.1 ± 13.9 | ||||||
6 M | 149.5 ± 14.8** | 156.2 ± 17.6 | ||||||
12 M | 144.0 ± 16.9* | 157.8 ± 10.3 | 0.12 | |||||
DBP†† | 0 | 44 | 70.9 ± 11.4 | 0.09 | 21 | 62.0 ± 15.7 | 0.46 | 0.09 |
3 M | 70.6 ± 12.3 | 64.5 ± 13.5 | ||||||
6 M | 69.6 ± 12.5 | 61.5 ± 16.5 | ||||||
12 M | 67.7 ± 13.8 | 63.8 ± 20.4 | 0.38 | |||||
PP††† | 0 | 44 | 74.6 ± 19.5 | 0.04 | 21 | 64.3 ± 16.1 | 0.02 | 0.24 |
3 M | 72.9 ± 20.0 | 66.5 ± 19.2 | ||||||
6 M | 72.1 ± 17.0 | 77.3 ± 14.5**** | ||||||
12 M | 68.0 ± 16.6*** | 68.8 ± 14.2 | 0.84 |